1. Initial pharmacotherapy for ST-segment elevation myocardial infarction
Initial pharmacotherapy for ST-segment elevation myocardial infarction. aFor at least 48 hours. bSee Table 7-2 for dosing and specific types of patients who should not receive enoxaparin. cFor the duration of hospitalization, up to 8 days. dFor selected patients, see Table 7-2. eIf pretreated with UFH, stop UFH infusion for 30 minutes prior to administration of bivalirudin (bolus plus infusion). fIncreased risk of major bleeding and intracranial hemorrhage if a GP IIb/IIIa inhibitor is added to an anticoagulant for PCI following fibrinolysis, especially in the elderly; weight risk versus benefit. (ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; GP, glycoprotein; NTG, nitroglycerin; PCI, percutaneous coronary intervention; Subcut, subcutaneous; SL, sublingual; UFH, unfractionated heparin.) (Modified with permission from Spinler SA. Evolution of antithrombotic therapy used in acute coronary syndromes. In: Richardson MM, Chant C, Cheng JWM, et al., eds. Pharmacotherapy Self-Assessment Program. Book 1: Cardiology, 7th ed. Lenexa, KS: American College of Clinical Pharmacy, 2010.)
Source: Chapter 7. Acute Coronary Syndromes, Pharmacotherapy: A Pathophysiologic Approach, 9e
Citation: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. Pharmacotherapy: A Pathophysiologic Approach, 9e; 2014 Available at: Accessed: November 09, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved